← Open Payments lookup

NPI 1427074285: Open Payments

NPI 1427074285. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,741 in 96 payments from 14 companies in 2025. Trend: 2023 $1,051 · 2024 $1,576 · 2025 $1,741

Food & beverage: $1,662Education: $80
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)14$247
Otsuka America Pharmaceutical, Inc.12$231
Teva Pharmaceuticals USA, Inc.11$226
Axsome Therapeutics, Inc.12$221
Almatica Pharma LLC9$149
Janssen Pharmaceuticals, Inc7$142
Takeda Pharmaceuticals U.S.A., Inc.7$118
Alkermes, Inc.6$108
Vanda Pharmaceuticals Inc.6$103
Neurocrine BioSciences, Inc.4$65

Products named: REXULTI, CAPLYTA, Auvelity, LOREEV XR, AUSTEDO XR, SPRAVATO, TRINTELLIX, FANAPT.